Impairment of JCV-specific T-cell response by corticotherapy: Effect on PML-IRIS management

Neurology

Volumn 79, Issue 23, 2012, Pages 2258-2264

  Antoniol, Caroline ^a,b   Jilek, Samantha ^a   Schluep, Myriam ^b   Mercier, Noëlle ^b   Canales, Mathieu ^a   Le Goff, Géraldine ^b   Campiche, Claudia ^b   Pantaleo, Giuseppe ^a,b   Du Pasquier, Renaud A ^a,b  

^a Division of Immunology and Allergy   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD45RA ANTIGEN; CHEMOKINE RECEPTOR CCR7; GAMMA INTERFERON; METHYLPREDNISOLONE; NATALIZUMAB; PREDNISONE; THYMIDINE; TUMOR NECROSIS FACTOR ALPHA; VIRUS DNA;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL FEATURE; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFLUENZA VIRUS; JC VIRUS; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MULTIPLE SCLEROSIS; NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; SEROLOGY; URINALYSIS;

EID: 84871296357     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182768983     Document Type: Article

References (19)

1. Marzocchetti A, Tompkins T, Clifford DB, et al. Determinants of survival in progressive multifocal leukoencephalopathy. Neurology 2009;73:1551-1558.
2. Vermersch P, Kappos L, Gold R, et al. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology 2011;76:1697-1704.
3. McCarthy M, Nath A. Neurologic consequences of the immune reconstitution inflammatory syndrome (IRIS). Curr Neurol Neurosci Rep 2010;10:467-475.
4. Wuthrich C, Kesari S, Kim WK, et al. Characterization of lymphocytic infiltrates in progressive multifocal leukoencephalopathy: co-localization of CD8(1) T cells with JCV-infected glial cells. J Neurovirol 2006;12:116-128.
5. Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010;9:438-446.
6. Du Pasquier RA, Koralnik IJ. Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial J Neurovirol 2003;9(suppl 1):25-31.
7. Du Pasquier RA, Kuroda MJ, Zheng Y, Jean-Jacques J, Letvin NL, Koralnik IJ. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain 2004;127:1970-1978.
8. Tan K, Roda R, Ostrow L,McArthur J, Nath A. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 2009;72:1458-1464.
9. Braun CM, Huang SK, Bashian GG, Kagey-Sobotka A, Lichtenstein LM, Essayan DM. Corticosteroid modulation of human, antigen-specific Th1 and Th2 responses. J Allergy Clin Immunol 1997;100:400-407.
10. Ashcraft KA, Hunzeker J, Bonneau RH. Psychological stress impairs the local CD81 T cell response to mucosal HSV-1 infection and allows for increased pathogenicity via a glucocorticoid receptor-mediated mechanism. Psychoneuroendocrinology 2008;33:951-963.
11. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127.
12. Jilek S, Schluep M, Meylan P, et al. Strong EBV-specific CD81 T-cell response in patients with early multiple sclerosis. Brain 2008;131:1712-1721.
13. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010;68:295-303.
14. Du Pasquier RA, Kuroda MJ, Schmitz JE, et al. Low frequency of cytotoxic T lymphocytes against the novel HLA-A 0201-restricted JC virus epitope VP1(p36) in patients with proven or possible progressive multifocal leukoencephalopathy. J Virol 2003;77:11918-11926.
15. Jilek S, Jaquiery E, Hirsch HH, et al. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study. Lancet Neurol 2010;9:264-272.
16. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004;22:745-763.
17. Zen M, Canova M, Campana C, et al. The kaleidoscope of glucocorticoid effects on immune system. Autoimmun Rev 2011;10:305-310.
18. Sloka JS, Stefanelli M. The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult Scler 2005;11:425-432.
19. Gotto J, Webster GJ, Brown D, Jenkins J, Dusheiko GM, Bertoletti A. The impact of HBV-DNA fluctuations on virus-specific CD81 T cells in HBeAg1 chronic hepatitis B patients treated with a steroid and lamivudine. J Viral Hepat 2006;13:415-425.